Argus raises McKesson stock price target to $1,050 on growth focus

Argus raised its McKesson (MCK) price target to $1,050 from $950 while maintaining a Buy, joining other firms with bullish targets (Leerink $1,085, TD Cowen $1,012, Evercore $1,000, BofA $970); the stock has returned 47% over the past year. The upgrade cites redeployment into higher-growth, higher-margin businesses (U.S. Oncology, PRISM eyecare, specialty medicine distribution/cold storage) after exiting non-core assets. McKesson announced CFO Britt Vitalone will retire and be succeeded by Kenny Cheung effective May 29, 2026, with Vitalone staying on as a strategic advisor to help the planned separation of the Medical-Surgical Solutions segment. Overall the report signals continued analyst confidence and positive momentum for the stock and strategic repositioning.

Analysis

McKesson’s pivot into higher-growth, higher-margin specialty channels (oncology, cold-chain specialty meds, eyecare services) is a classic margin-conversion story: shifting a modest portion of revenue mix (mid-single-digit % over 24–36 months) into businesses that trade at 200–400bps higher operating margins can drive outsized EPS leverage without material top-line growth. That levered margin effect also magnifies free cash flow conversion and creates optionality for bolt-on tuck-ins or accelerated buybacks once separation-related clarity arrives.

Second-order winners include cold-chain logistics vendors, specialty pharmacy fulfillment platforms, and oncology services providers that can scale under McKesson’s distribution footprint — expect pricing pressure on smaller regional wholesalers that lack capital to upgrade infrastructure, creating consolidation tailwinds for the next 12–36 months. Pharma manufacturers that outsource specialty distribution will face tougher commercial terms but gain reliability in handling complex SKUs, which could shorten launch cycles for high-margin biologics and devices.

Execution and corporate-event risks dominate near-term returns: the planned separation and CFO transition compress the window for smooth integration and could produce one-time charges or capital allocation drift in the next 3–12 months. The structural thesis reverses if GLP-1/other specialty volumes decelerate meaningfully or if payer pushback (rebate clawbacks or stricter site-of-care policies) materializes — those are 6–24 month downside scenarios that would compress multiple and margin expectations quickly.

Key Decisions for Investors

• Long MCK (conviction): buy on weakness within next 3 months, target +25% over 12–18 months, stop-loss -12% — rationale: margin mix shift + separation optionality; expected asymmetry if execution stays on track.
• Pair trade (risk-off hedge): long MCK / short CAH equal notional for 12–18 months — captures relative execution and capex advantage; target spread narrowing of 15–25% with a max drawdown of 10% on the pair.
• Options idea (capital-efficient): buy 12–18 month MCK call spread (bull call) to cap premium — sizing 2–3% notional; aim for 3:1 upside if separation or specialty ramp catalysts land, limited downside to premium paid.
• Event trade: set a watch for separation/CFO transition updates (next 3–6 months); add size on any >8% intraday sell-off tied to personnel noise, take profits on strong post-update outperformance within 30–90 days.